Search

Displaying results 1041 - 1050 of 7499 in total
  1. Drug

    L-Glutamine

    go.drugbank.com/drugs/DB00130
    ApprovedInvestigationalNutraceutical

    An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. … A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia.

  2. Drug

    Pretomanid

    go.drugbank.com/drugs/DB05154
    ApprovedInvestigational

    It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. … [L8048,L8066] Unlike other therapeutic regimens for the treatment of resistant TB, which may take 18 months or longer and may not be effective, the pretomanid-containing regimen allows for a more efficacious

  3. Drug

    Ertugliflozin

    go.drugbank.com/drugs/DB11827
    ApprovedInvestigational

    [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.

  4. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

    Synonyms: N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea
  5. Drug

    Bedaquiline

    go.drugbank.com/drugs/DB08903
    ApprovedInvestigational

    [A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.

  6. Drug

    Nonacog beta pegol

    go.drugbank.com/drugs/DB13933
    ApprovedInvestigational

    [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017,[L1098] followed by the European Commission approval on June 2, 2017. … [L41185] Nonacog beta pegol was approved by Health Canada on November 29, 2017.[L43682]

  7. Drug

    Tecovirimat

    go.drugbank.com/drugs/DB12020
    ApprovedInvestigational

    [A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox. … [L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022.

  8. Drug

    Acetylcysteine

    go.drugbank.com/drugs/DB06151
    ApprovedInvestigational

    [A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488]

    Mixtures: AMINOSTERIL N-HEPA 500 ML SOLUSYON, N-ACETILCISTEÍNA MAS GUAYACOLATO DE GLICERILOSynonyms: N-AC, N-acetylcysteine
  9. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. … This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.

    Synonyms: Interferon alfa-n1, Interferon alpha-n1 (INS)Categories: interferon alfa-n1
  10. Drug

    Magnesium oxide

    go.drugbank.com/drugs/DB01377
    ApprovedInvestigational

    In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.

    Mixtures: Super Daily No 2, UltimateCare ONE NF